Letermovir and Inhibitors of the Terminase Complex: a Promising New Class of Investigational Antiviral Drugs Against Human Cytomegalovirus

Overview

Journal Infect Drug Resist

Publisher Dove Medical Press

Date 2015 Sep 9

PMID 26345608

Citations 33

Authors

Dante P Melendez

Raymund R Razonable

Affiliations

Soon will be listed here.

Abstract

Infection with cytomegalovirus is prevalent in immunosuppressed patients. In solid organ transplant and hematopoietic stem cell transplant recipients, cytomegalovirus infection is associated with high morbidity and preventable mortality. Prevention and treatment of cytomegalovirus with currently approved antiviral drugs is often associated with side effects that sometimes preclude their use. Moreover, cytomegalovirus has developed mutations that confer resistance to standard antiviral drugs. During the last decade, there have been calls to develop novel antiviral drugs that could provide better options for prevention and treatment of cytomegalovirus. Letermovir (AIC246) is a highly specific antiviral drug that is currently undergoing clinical development for the management of cytomegalovirus infection. It acts by inhibiting the viral terminase complex. Letermovir is highly potent in vitro and in vivo against cytomegalovirus. Because of a distinct mechanism of action, it does not exhibit cross-resistance with other antiviral drugs. It is predicted to be active against strains that are resistant to ganciclovir, foscarnet, and cidofovir. To date, early-phase clinical trials suggest a very low incidence of adverse effects. Herein, we present a comprehensive review on letermovir, from its postulated novel mechanism of action to the results of most recent clinical studies.

Citing Articles

Current and Emerging Antiviral Agents in the Prevention and Treatment of Cytomegalovirus in Pediatric Transplant Recipients.

Valencia Deray K, Danziger-Isakov L, Downes K J Pediatric Infect Dis Soc. 2024; 13(Supplement_1):S14-S21.

PMID: 38417084 PMC: 10901473. DOI: 10.1093/jpids/piad059.

Peptide-to-Small Molecule: Discovery of Non-Covalent, Active-Site Inhibitors of β-Herpesvirus Proteases.

Yoshida S, Sako Y, Nikaido E, Ueda T, Kozono I, Ichihashi Y ACS Med Chem Lett. 2023; 14(11):1558-1566.

PMID: 37974946 PMC: 10641906. DOI: 10.1021/acsmedchemlett.3c00359.

Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide-based transplant.

Lin A, Brown S, Chinapen S, Lee Y, Seo S, Ponce D Blood Adv. 2023; 7(23):7153-7160.

PMID: 37906513 PMC: 10698256. DOI: 10.1182/bloodadvances.2023010966.

Antiviral Approach to Cytomegalovirus Infection: An Overview of Conventional and Novel Strategies.

Bottino P, Pastrone L, Curtoni A, Bondi A, Sidoti F, Zanotto E Microorganisms. 2023; 11(10).

PMID: 37894030 PMC: 10608897. DOI: 10.3390/microorganisms11102372.

Chemistry and Pharmacology of Fluorinated Drugs Approved by the FDA (2016-2022).

Shabir G, Saeed A, Zahid W, Naseer F, Riaz Z, Khalil N Pharmaceuticals (Basel). 2023; 16(8).

PMID: 37631077 PMC: 10458641. DOI: 10.3390/ph16081162.

References

Goldner T, Hempel C, Ruebsamen-Schaeff H, Zimmermann H, Lischka P . Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. Antimicrob Agents Chemother. 2013; 58(1):610-3. PMC: 3910730. DOI: 10.1128/AAC.01794-13. View

Champier G, Couvreux A, Hantz S, Rametti A, Mazeron M, Bouaziz S . Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. Antivir Ther. 2008; 13(5):643-54. View

Weis K, Dingwall C, Lamond A . Characterization of the nuclear protein import mechanism using Ran mutants with altered nucleotide binding specificities. EMBO J. 1996; 15(24):7120-8. PMC: 452537. View

Lurain N, Chou S . Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev. 2010; 23(4):689-712. PMC: 2952978. DOI: 10.1128/CMR.00009-10. View

Borst E, Kleine-Albers J, Gabaev I, Babic M, Wagner K, Binz A . The human cytomegalovirus UL51 protein is essential for viral genome cleavage-packaging and interacts with the terminase subunits pUL56 and pUL89. J Virol. 2012; 87(3):1720-32. PMC: 3554196. DOI: 10.1128/JVI.01955-12. View

Torre-Cisneros J . Toward the individualization of cytomegalovirus control after solid-organ transplantation: the importance of the "individual pathogenic balance". Clin Infect Dis. 2009; 49(8):1167-8. DOI: 10.1086/605634. View

Krosky P, Underwood M, Turk S, Feng K, Jain R, Ptak R . Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56. J Virol. 1998; 72(6):4721-8. PMC: 110001. DOI: 10.1128/JVI.72.6.4721-4728.1998. View

Stoelben S, Arns W, Renders L, Hummel J, Muhlfeld A, Stangl M . Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study. Transpl Int. 2013; 27(1):77-86. DOI: 10.1111/tri.12225. View

Giesen K, Radsak K, Bogner E . The potential terminase subunit of human cytomegalovirus, pUL56, is translocated into the nucleus by its own nuclear localization signal and interacts with importin alpha. J Gen Virol. 2000; 81(Pt 9):2231-2244. DOI: 10.1099/0022-1317-81-9-2231. View

10.

Manuel O, Pang X, Humar A, Kumar D, Doucette K, Preiksaitis J . An assessment of donor-to-recipient transmission patterns of human cytomegalovirus by analysis of viral genomic variants. J Infect Dis. 2009; 199(11):1621-8. DOI: 10.1086/598952. View

11.

Humar A, Lebranchu Y, Vincenti F, Blumberg E, Punch J, Limaye A . The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant. 2010; 10(5):1228-37. DOI: 10.1111/j.1600-6143.2010.03074.x. View

12.

Komazin G, Townsend L, Drach J . Role of a mutation in human cytomegalovirus gene UL104 in resistance to benzimidazole ribonucleosides. J Virol. 2003; 78(2):710-5. PMC: 368810. DOI: 10.1128/jvi.78.2.710-715.2004. View

13.

Kaul D, Stoelben S, Cober E, Ojo T, Sandusky E, Lischka P . First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant. 2011; 11(5):1079-84. DOI: 10.1111/j.1600-6143.2011.03530.x. View

14.

Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B . Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2004; 4(4):611-20. DOI: 10.1111/j.1600-6143.2004.00382.x. View

15.

Reddehase M . Antigens and immunoevasins: opponents in cytomegalovirus immune surveillance. Nat Rev Immunol. 2002; 2(11):831-44. DOI: 10.1038/nri932. View

16.

Einsele H, Hebart H, Sinzger C, Jahn G, Bader P, Klingebiel T . Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant. 2000; 25(7):757-63. DOI: 10.1038/sj.bmt.1702226. View

17.

Goldner T, Hewlett G, Ettischer N, Ruebsamen-Schaeff H, Zimmermann H, Lischka P . The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol. 2011; 85(20):10884-93. PMC: 3187482. DOI: 10.1128/JVI.05265-11. View

18.

Reefschlaeger J, Bender W, Hallenberger S, Weber O, Eckenberg P, Goldmann S . Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action. J Antimicrob Chemother. 2001; 48(6):757-67. DOI: 10.1093/jac/48.6.757. View

19.

Bogner E, Radsak K, Stinski M . The gene product of human cytomegalovirus open reading frame UL56 binds the pac motif and has specific nuclease activity. J Virol. 1998; 72(3):2259-64. PMC: 109523. DOI: 10.1128/JVI.72.3.2259-2264.1998. View

20.

Chemaly R, Ullmann A, Stoelben S, Richard M, Bornhauser M, Groth C . Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med. 2014; 370(19):1781-9. DOI: 10.1056/NEJMoa1309533. View